Polycaprolactone scaffold modified with galactosylated chitosan for hepatocyte culture

被引:27
作者
Qiu, Yuan [1 ,2 ]
Mao, Zhengwei [1 ]
Zhao, Yimu [1 ]
Zhang, Jichuan [1 ]
Guo, Qi [1 ]
Gou, Zhongru [2 ]
Gao, Changyou [1 ,3 ]
机构
[1] Zhejiang Univ, MOE Key Lab Macromol Synth & Functionalizat, Dept Polymer Sci & Engn, Hangzhou 310027, Peoples R China
[2] Zhejiang Calif Int NanoSyst Inst, Hangzhou 310012, Zhejiang, Peoples R China
[3] Zhejiang Univ, State Key Lab Diag & Treatment Infect Dis, Affiliated Hosp 1, Coll Med, Hangzhou 310003, Zhejiang, Peoples R China
关键词
polycaprolactone; galactosylated chitosan; hepatocytes; biocartificial liver; surface modification; SYNTHETIC EXTRACELLULAR-MATRIX; BIOARTIFICIAL LIVER; IN-VITRO; BIODEGRADABLE POLYMERS; ATTACHMENT; BIOMATERIALS; IMMOBILIZATION; MICROCARRIERS; MICROSPHERES; SPHEROIDS;
D O I
10.1007/s13233-012-0056-8
中图分类号
O63 [高分子化学(高聚物)];
学科分类号
070305 ; 080501 ; 081704 ;
摘要
A suitable extracellular matrix that can maintain long-term proliferation and liver-specific functions of hepatocytes is essential for both extracorporeal bioartificial liver (BAL) assist systems and implantable cell-scaffold constructs. In this work, a polycaprolactone (PCL) scaffold was modified with galactosylated chitosan (GC) to achieve better bioactivity and mechanical stability. The PCL scaffold, prepared by a method of gelatin particle leaching, was hydrolyzed to produce carboxylic groups that were utilized to react with the amine groups of the GC, which was synthesized by grafting the galactose to chitosan. Results showed that the content of carboxylic groups was increased initially with the hydrolysis time until 10 min, at which a COOH density of 2.0x10(-5) mol/mg scaffold was reached. The incorporated GC amount showed a positive relationship with the COOH density and finally reached a 100 mu g/mg scaffold with a hydrolysis time of 15 min. The incorporated GC was rather stable against incubation in the medium, and could significantly enhance the compression strength of the PCL scaffold in a wet state. With the galactose ligands on the surface, the PCL scaffold could be better recognized by hepatocytes, and show better cell viability, spheroid formation and long-term maintenance of liver-specific functions such as albumin secretion.
引用
收藏
页码:283 / 291
页数:9
相关论文
共 40 条
[1]   The three-dimensional cultivation of the carcinoma cell line HepG2 in a perfused chip system leads to a more differentiated phenotype of the cells compared to monolayer culture [J].
Altmann, B. ;
Giselbrecht, S. ;
Weibezahn, K-F ;
Welle, A. ;
Gottwald, E. .
BIOMEDICAL MATERIALS, 2008, 3 (03)
[2]   In vitro evaluation of a multi-layer radial-flow bioreactor based on galactosylated chitosan nanofiber scaffolds [J].
Chu, Xue-Hui ;
Shi, Xiao-Lei ;
Feng, Zhang-Qi ;
Gu, Jin-Yang ;
Xu, Hai-Yun ;
Zhang, Yue ;
Gu, Zhong-Ze ;
Ding, Yi-Tao .
BIOMATERIALS, 2009, 30 (27) :4533-4538
[3]   Stable immobilization of rat hepatocyte spheroids on galactosylated nanofiber scaffold [J].
Chua, KN ;
Lim, WS ;
Zhang, PC ;
Lu, HF ;
Wen, J ;
Ramakrishna, S ;
Leong, KW ;
Mao, HQ .
BIOMATERIALS, 2005, 26 (15) :2537-2547
[4]   Preparation of alginate/galactosylated chitosan scaffold for hepatocyte attachment [J].
Chung, TW ;
Yang, J ;
Akaike, T ;
Cho, KY ;
Nah, JW ;
Kim, SI ;
Cho, CS .
BIOMATERIALS, 2002, 23 (14) :2827-2834
[5]   Synthetic sandwich culture of 3D hepatocyte monolayer [J].
Du, Yanan ;
Han, Rongbin ;
Wen, Feng ;
San, Susanne Ng San ;
Xia, Lei ;
Wohland, Thorsten ;
Leo, Hwa Liang ;
Yu, Hanry .
BIOMATERIALS, 2008, 29 (03) :290-301
[6]   3D hepatocyte monolayer on hybrid RGD/galactose substratum [J].
Du, Yanan ;
Chia, Ser-mien ;
Han, Rongbin ;
Chang, Shi ;
Tang, Huihuan ;
Yu, Hanry .
BIOMATERIALS, 2006, 27 (33) :5669-5680
[7]   The effect of nanofibrous galactosylated chitosan scaffolds on the formation of rat primary hepatocyte aggregates and the maintenance of liver function [J].
Feng, Zhang-Qi ;
Chu, Xuehui ;
Huang, Ning-Ping ;
Wang, Tao ;
Wang, Yichun ;
Shi, Xiaolei ;
Ding, Yitao ;
Gu, Zhong-Ze .
BIOMATERIALS, 2009, 30 (14) :2753-2763
[8]   Bioartificial liver systems: why, what, whither? [J].
Gerlach, Joerg C. ;
Zedinger, Katrin ;
Patzer, John F., II .
REGENERATIVE MEDICINE, 2008, 3 (04) :575-595
[9]  
Glicklis R, 2000, BIOTECHNOL BIOENG, V67, P344, DOI 10.1002/(SICI)1097-0290(20000205)67:3<344::AID-BIT11>3.0.CO
[10]  
2-2